We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+43.82%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.32B
AUM Growth
+$367M
Cap. Flow
+$106M
Cap. Flow %
8.07%
Top 10 Hldgs %
60.28%
Holding
65
New
6
Increased
15
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$74.1M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$64.1M
3
CYTK icon
Cytokinetics
CYTK
+$31.2M
4
PHAT icon
Phathom Pharmaceuticals
PHAT
+$19.8M
5
XOMA
Xoma
XOMA
+$18.9M

Top Sells

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$46.6M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$24.1M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$24.1M
4
MRUS
Merus
MRUS
+$23.6M
5
BPMC
Blueprint Medicines
BPMC
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 95.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XFOR icon
26
X4 Pharmaceuticals
XFOR
$374M
$12.2M 0.93%
38,066
+18,284
+92% +$6.56M
CTIC
27
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$10.9M 0.83%
6,929,690
– –
IDYA icon
28
IDEAYA Biosciences
IDYA
$3.41B
$10.8M 0.82%
1,436,429
-5,000
-0.3% -$35.7K
GLMD icon
29
Galmed Pharmaceuticals
GLMD
$4.82M
$10.6M 0.8%
10,180
– –
PRVL
30
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$10.4M 0.79%
656,483
– –
CDTX
31
DELISTED
Cidara Therapeutics
CDTX
$10.3M 0.78%
134,387
– –
AKRO
32
DELISTED
Akero Therapeutics
AKRO
$10M 0.76%
451,009
-20,737
-4% -$429K
CRVS icon
33
Corvus Pharmaceuticals
CRVS
$1.1B
$8.85M 0.67%
1,627,568
-1,419,587
-47% -$4.97M
VSTM icon
34
Verastem
VSTM
$490M
$8.48M 0.64%
527,416
– –
SPRO icon
35
Spero Therapeutics
SPRO
$68.3M
$8.13M 0.62%
845,405
-94,299
-10% -$1.02M
RNAC icon
36
Cartesian Therapeutics
RNAC
$219M
$7.82M 0.59%
+109,469
New +$5.28M
MRSN
37
DELISTED
Mersana Therapeutics
MRSN
$6.76M 0.51%
47,222
-114,454
-71% -$8.37M
CTMX icon
38
CytomX Therapeutics
CTMX
$686M
$6.37M 0.48%
766,148
-1,111,000
-59% -$7.5M
FWP
39
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$6.01M 0.46%
925,724
-2
-0% -$13
PTGX icon
40
Protagonist Therapeutics
PTGX
$8.73B
$4.81M 0.36%
682,630
– –
PHXM
41
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$4.55M 0.35%
62,500
– –
ALPN
42
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.37M 0.33%
1,137,764
– –
GNCA
43
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.35M 0.33%
2,100,305
– –
GMDA
44
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$4.3M 0.33%
1,000,000
– –
ARGX icon
45
argenx
ARGX
$53.6B
$4.01M 0.3%
+25,000
New +$3.38M
BLRX
46
BioLineRX
BLRX
$12M
$3.9M 0.3%
43,326
– –
STRO icon
47
Sutro Biopharma
STRO
$405M
$3.8M 0.29%
34,520
+100
+0.3% +$10.3K
OVID icon
48
Ovid Therapeutics
OVID
$416M
$3.05M 0.23%
734,301
-1,586,935
-68% -$5.01M
EIGR
49
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.14M 0.16%
4,786
-13,198
-73% -$4.68M
VIRX
50
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.09M 0.16%
176,998
– –
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2019 Portfolio in Review

As of Q4 2019, BVF Inc held 65 positions worth $1.32B, up 39% from $952M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

BVF Inc deployed $106M of net new capital in Q4 2019, opening 6 new positions and adding to 15 existing holdings. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,716,734 shares worth $94M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $23.6M trimmed.

  • BVF Inc's largest Q4 2019 buy was Principia Biopharma Inc. Common Stock: 1,716,734 shares worth $94M.
  • BVF Inc added most to Ionis Pharmaceuticals in Q4 2019, an estimated $74.1M increase.
  • BVF Inc's biggest Q4 2019 reduction was Merus, cutting an estimated $23.6M.
  • BVF Inc fully exited Lakefront Biotherapeutics American Depositary Shares in Q4 2019, selling an estimated $46.6M.
  • BVF Inc's ten largest holdings make up 60% of its $1.32B portfolio in Q4 2019.
  • BVF Inc opened 6 new positions and closed 8 in Q4 2019.
  • BVF Inc's portfolio value rose 39% quarter-over-quarter to $1.32B.

Based on BVF Inc's 13F filing for Q4 2019, filed 14 Feb 2020.